Prognostic Role of Immune Infiltrates in Breast Ductal Carcinoma in Situ

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2019 May 29

PMID 31134489

Citations 27

Authors

Xiao-Yang Chen

Joe Yeong

Aye Aye Thike

Boon Huat Bay

Puay Hoon Tan

Affiliations

Soon will be listed here.

Abstract

Purpose: Ductal carcinoma in situ (DCIS) of the breast is often regarded as a non-obligate precursor to invasive breast carcinoma but current diagnostic tools are unable to accurately predict the invasive potential of DCIS. Infiltration of immune cells into the tumour and its microenvironment is often an early event at the site of tumourigenesis. These immune infiltrates may be potential predictive and/or prognostic biomarkers for DCIS. This review aims to discuss recent findings pertaining to the potential prognostic significance of immune infiltrates as well as their evaluation in DCIS.

Methods: A literature search on PubMed was conducted up to 28th January 2019. Search terms used were "DCIS", "ductal carcinoma in situ", "immune", "immunology", "TIL", "TIL assessment", and "tumour-infiltrating lymphocyte". Search filters for "Most Recent" and "English" were applied. Information from published papers related to the research topic were synthesised and summarised for this review.

Results: Studies have revealed that immune infiltrates play a role in the biology and microenvironment of DCIS, as well as treatment response. There is currently no consensus on the evaluation of TILs in DCIS for clinical application.

Conclusions: This review highlights the recent findings on the potential influence and prognostic value of immunological processes on DCIS progression, as well as the evaluation of TILs in DCIS. Further characterisation of the immune milieu of DCIS is recommended to better understand the immune response in DCIS progression and recurrence.

Citing Articles

Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.

Pasetto C, Aguiar F, Peixoto M, Doria M, Mota B, Maesaka J Breast Cancer Res Treat. 2024; 208(1):9-18.

PMID: 39180593 DOI: 10.1007/s10549-024-07466-9.

Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes.

Ciarka A, Piatek M, Peksa R, Kunc M, Senkus E Biomedicines. 2024; 12(4).

PMID: 38672117 PMC: 11048219. DOI: 10.3390/biomedicines12040763.

Clinical implications of forkhead box M1, cyclooxygenase-2 and glucose-regulated protein 78 in breast invasive ductal carcinoma.

Bai J, Li Y, Cai L World J Clin Cases. 2023; 11(30):7284-7293.

PMID: 37969442 PMC: 10643068. DOI: 10.12998/wjcc.v11.i30.7284.

Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.

Liu Y, Yu T J Cancer Res Clin Oncol. 2023; 149(13):11181-11191.

PMID: 37354223 PMC: 10465373. DOI: 10.1007/s00432-023-04895-9.

Performance of a PLK1-based immune risk model for prognosis and treatment response prediction in breast cancer.

Chen Y, You Y, Wu Q, Wu J, Lin S, Sun Y Cancer Med. 2023; 12(9):11020-11039.

PMID: 36951624 PMC: 10225204. DOI: 10.1002/cam4.5813.

References

Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V . Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015; 152(2):293-304. DOI: 10.1007/s10549-015-3472-6. View

Cowell C, Weigelt B, Sakr R, Ng C, Hicks J, King T . Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol. 2013; 7(5):859-69. PMC: 5528459. DOI: 10.1016/j.molonc.2013.07.005. View

Doebar S, van den Broek E, Koppert L, Jager A, Baaijens M, Obdeijn I . Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Res Treat. 2016; 158(1):179-187. PMC: 4937080. DOI: 10.1007/s10549-016-3862-4. View

Schnitt S . The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res. 2009; 11(1):101. PMC: 2687714. DOI: 10.1186/bcr2228. View

Damonte P, Hodgson J, Chen J, Young L, Cardiff R, Borowsky A . Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res. 2008; 10(3):R50. PMC: 2481504. DOI: 10.1186/bcr2104. View

Knudsen E, Ertel A, Davicioni E, Kline J, Schwartz G, Witkiewicz A . Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat. 2011; 133(3):1009-24. DOI: 10.1007/s10549-011-1894-3. View

Gao Y, Niu Y, Wang X, Wei L, Lu S . Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J Mol Med (Berl). 2008; 87(2):145-52. DOI: 10.1007/s00109-008-0408-1. View

Carraro D, Elias E, Andrade V . Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression. Biosci Rep. 2016; 34(1). PMC: 3894794. DOI: 10.1042/BSR20130077. View

Waldman F, DeVries S, Chew K, Moore 2nd D, Kerlikowske K, Ljung B . Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst. 2000; 92(4):313-20. DOI: 10.1093/jnci/92.4.313. View

10.

Fleischer T, Frigessi A, Johnson K, Edvardsen H, Touleimat N, Klajic J . Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol. 2014; 15(8):435. PMC: 4165906. DOI: 10.1186/PREACCEPT-2333349012841587. View

11.

Pang J, Dobrovic A, Fox S . DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res. 2013; 15(3):206. PMC: 3707020. DOI: 10.1186/bcr3420. View

12.

Ma X, Salunga R, Tuggle J, Gaudet J, Enright E, McQuary P . Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003; 100(10):5974-9. PMC: 156311. DOI: 10.1073/pnas.0931261100. View

13.

Pang J, Savas P, Fellowes A, Arnau G, Kader T, Vedururu R . Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Mod Pathol. 2017; 30(7):952-963. DOI: 10.1038/modpathol.2017.21. View

14.

Ottesen G, Christensen I, Larsen J, Larsen J, Christiansen J, Baldetorp B . DNA ploidy analysis in breast carcinoma. Comparison of unfixed and fixed tissue analyzed by image and flow cytometry. Anal Quant Cytol Histol. 1997; 19(5):413-22. View

15.

Giardina C, Serio G, Lepore G, Lettini T, Dalena A, Pennella A . Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study. J Exp Clin Cancer Res. 2003; 22(2):279-88. View

16.

Page D, Dupont W, Rogers L, Landenberger M . Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982; 49(4):751-8. DOI: 10.1002/1097-0142(19820215)49:4<751::aid-cncr2820490426>3.0.co;2-y. View

17.

Sanders M, Schuyler P, Dupont W, Page D . The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005; 103(12):2481-4. DOI: 10.1002/cncr.21069. View

18.

Page D, Dupont W, Rogers L, Jensen R, Schuyler P . Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995; 76(7):1197-200. DOI: 10.1002/1097-0142(19951001)76:7<1197::aid-cncr2820760715>3.0.co;2-0. View

19.

Abdel-Fatah T, Powe D, Hodi Z, Lee A, Reis-Filho J, Ellis I . High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007; 31(3):417-26. DOI: 10.1097/01.pas.0000213368.41251.b9. View

20.

Bryan B, Schnitt S, Collins L . Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006; 19(5):617-21. DOI: 10.1038/modpathol.3800570. View